AI
Wednesday, April 02, 2008 9:52:37 AM
Dew or Genisi:
I more-or-less
understand that GTC has a recombinant product as opposed to Kamada's plasma-derived AAT.
Is the posting of their news simply a prudent and valuable continuation of the "keeping track of the competition" strategy, or are you posting it because it might have immediate relevance to GTC's stock price or ongoing partnership discussions? If the latter, could you elaborate? TIA.
I more-or-less
understand that GTC has a recombinant product as opposed to Kamada's plasma-derived AAT. Is the posting of their news simply a prudent and valuable continuation of the "keeping track of the competition" strategy, or are you posting it because it might have immediate relevance to GTC's stock price or ongoing partnership discussions? If the latter, could you elaborate? TIA.
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
